AVBP FY 2023 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$75M

Net Income

-$69M

EPS (Diluted)

$-2.17

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$56M

Stock-Based Comp.

$895,000

Balance Sheet

Total Assets

$163M

Total Liabilities

$12M

Stockholders' Equity

$151M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$75M	-$37M	-102.1%
Net Income	-$69M	-$37M	-87.9%